Alteration of Cellular Behavior and Response to PI3K Pathway Inhibition by Culture in 3D Collagen Gels

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Fallica, Brian ^a   Maffei, Joseph S ^a   Villa, Shaun ^b   Makin, Guy ^b,c   Zaman, Muhammad ^a  

^a Boston University   (United States)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; COLLAGEN GEL; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CELL FUNCTION; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CELL TRACKING; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; OSTEOSARCOMA CELL; PROTEIN EXPRESSION;

APOPTOSIS; BLOTTING, WESTERN; CELL ADHESION; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COLLAGEN TYPE I; EXTRACELLULAR MATRIX; FURANS; GELS; HUMANS; MCF-7 CELLS; MICROSCOPY, CONFOCAL; MICROSCOPY, VIDEO; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PYRIDINES; PYRIMIDINES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84867874282     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048024     Document Type: Article

References (57)

1. National Cancer Institute (2011) SEER Cancer Statistics Review 1975-2008.
2. Tornóczky T, Kövér E, Pajor L, (2003) Frequent occurrence of low grade cases among metastatic gastrointestinal stromal tumours. Journal of Clinical Pathology 56: 363-367 doi:10.1136/jcp.56.5.363.
3. Williams J, Lucas PC, Griffith KA, Choi M, Fogoros S, et al. (2005) Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease. Gynecologic Oncology 96: 287-295 doi:10.1016/j.ygyno.2004.10.026.
4. Gatti L, Zunino F, (2005) Overview of Tumor Cell Chemoresistance Mechanisms. Chemosensitivity: Volume II. Methods in Molecular Medicine. Humana Press, Vol. 111: 127-148-148.
5. Bates RC, Edwards NS, Burns GF, Fisher DE, (2001) A CD44 Survival Pathway Triggers Chemoresistance via Lyn Kinase and Phosphoinositide 3-Kinase/Akt in Colon Carcinoma Cells. Cancer Research 61: 5275-5283.
6. Hishikawa Y, Abe S, Kinugasa S, Yoshimura H, Monden N, et al. (1997) Overexpression of Metallothionein Correlates with Chemoresistance to Cisplatin and Prognosis in Esophageal Cancer. Oncology 54: 342-347.
7. Brown LM, Cowen RL, Debray C, Eustace A, Erler JT, et al. (2006) Reversing Hypoxic Cell Chemoresistance in Vitro Using Genetic and Small Molecule Approaches Targeting Hypoxia Inducible Factor-1. Molecular Pharmacology 69: 411-418.
8. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, et al. (2006) Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Molecular Cancer 5: 67.
9. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747-752 doi:10.1038/35021093.
10. Sotiriou C, Powles TJ, Dowsett M, Jazaeri AA, Feldman AL, et al. (2002) Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Research 4: R3 doi:10.1186/bcr433.
11. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, et al. (2008) Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy. Journal of the National Cancer Institute 100: 672-679 doi:10.1093/jnci/djn123.
12. Cukierman E, Pankov R, Stevens DR, Yamada KM, (2001) Taking Cell-Matrix Adhesions to the Third Dimension. Science 294: 1708-1712.
13. Barralet JE, Wang L, Lawson M, Triffitt JT, Cooper PR, et al. (2005) Comparison of bone marrow cell growth on 2D and 3D alginate hydrogels. Journal of Materials Science: Materials in Medicine 16: 515-519 doi:10.1007/s10856-005-0526-z.
14. Grinnell F, (2003) Fibroblast biology in three-dimensional collagen matrices. Trends in Cell Biology 13: 264-269 doi:10.1016/S0962-8924(03)00057-6.
15. Even-Ram S, Yamada KM, (2005) Cell migration in 3D matrix. Current Opinion in Cell Biology 17: 524-532 doi:10.1016/j.ceb.2005.08.015.
16. Baker EL, Srivastava J, Yu D, Bonnecaze RT, Zaman MH, (2011) Cancer Cell Migration: Integrated Roles of Matrix Mechanics and Transforming Potential. PLoS ONE 6: e20355 doi:10.1371/journal.pone.0020355.
17. Berrier AL, Yamada KM, (2007) Cell-matrix adhesion. J Cell Physiol 213: 565-573 doi:10.1002/jcp.21237.
18. Baker EL, Bonnecaze RT, Zaman MH, (2009) Extracellular Matrix Stiffness and Architecture Govern Intracellular Rheology in Cancer. Biophysical Journal 97: 1013-1021 doi:10.1016/j.bpj.2009.05.054.
19. Paszek MJ, Zahir N, Johnson KR, Lakins JN, Rozenberg GI, et al. (2005) Tensional homeostasis and the malignant phenotype. Cancer Cell 8: 241-254 doi:10.1016/j.ccr.2005.08.010.
20. Netti PA, Berk DA, Swartz MA, Grodzinsky AJ, Jain RK, (2000) Role of Extracellular Matrix Assembly in Interstitial Transport in Solid Tumors. Cancer Research 60: 2497-2503.
21. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS, (1999) Cell Adhesion Mediated Drug Resistance (CAM-DR): Role of Integrins and Resistance to Apoptosis in Human Myeloma Cell Lines. Blood 93: 1658-1667.
22. Marastoni S, Ligresti G, Lorenzon E, Colombatti A, Mongiat M, (2008) Extracellular Matrix: A Matter of Life and Death. Connective Tissue Research 49: 203-206.
23. Griffith LG, Swartz MA, (2006) Capturing complex 3D tissue physiology in vitro. Nat Rev Mol Cell Biol 7: 211-224 doi:10.1038/nrm1858.
24. Decaestecker C, Debeir O, Van Ham P, Kiss R, (2007) Can anti-migratory drugs be screened in vitro? A review of 2D and 3D assays for the quantitative analysis of cell migration. Medicinal Research Reviews 27: 149-176 doi:10.1002/med.20078.
25. Yamada KM, Cukierman E, (2007) Modeling Tissue Morphogenesis and Cancer in 3D. Cell 130: 601-610 doi:10.1016/j.cell.2007.08.006.
26. Leeman MF, McKay JA, Murray GI, (2002) Matrix metalloproteinase 13 activity is associated with poor prognosis in colorectal cancer. Journal of Clinical Pathology 55: 758-762 doi:10.1136/jcp.55.10.758.
27. Yoshizaki T, Maruyama Y, Sato H, Furukawa M (2001) AID-IJC1008>3.0.CO;2-M.
28. De Vicente J-C, Lequerica-Fernández P, Santamaría J, Fresno M-F, (2007) Expression of MMP-7 and MT1-MMP in oral squamous cell carcinoma as predictive indicator for tumor invasion and prognosis. Journal of Oral Pathology & Medicine 36: 415-424 doi:10.1111/j.1600-0714.2007.00546.x.
29. Ranuncolo SM, Armanasco E, Cresta C, Bal de Kier Joffe E, Puricelli L, (2003) Plasma MMP-9 (92 kDa-MMP) activity is useful in the follow-up and in the assessment of prognosis in breast cancer patients. International Journal of Cancer 106: 745-751 doi:10.1002/ijc.11288.
30. Anderson ARA, Weaver AM, Cummings PT, Quaranta V, (2006) Tumor Morphology and Phenotypic Evolution Driven by Selective Pressure from the Microenvironment. Cell 127: 905-915 doi:10.1016/j.cell.2006.09.042.
31. Anderson ARA, (2005) A hybrid mathematical model of solid tumour invasion: the importance of cell adhesion. Mathematical Medicine and Biology 22: 163-186 doi:10.1093/imammb/dqi005.
32. Carracedo A, Pandolfi PP, (2008) The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene 27: 5527-5541.
33. Courtney KD, Corcoran RB, Engelman JA, (2010) The PI3K Pathway As Drug Target in Human Cancer. Journal of Clinical Oncology 28: 1075-1083.
34. Guertin DA, Sabatini DM, (2007) Defining the Role of mTOR in Cancer. Cancer Cell 12: 9-22 doi:10.1016/j.ccr.2007.05.008.
35. Kubica N, Blenis J (2009) mTORC1: A Signaling Integration Node Involved in Cell Growth. In: Polunovsky VA, Houghton PJ, editors. mTOR Pathway and mTOR Inhibitors in Cancer Therapy. Totowa, NJ: Humana Press. 1-36. Available:http://www.springerlink.com/content/qp3007l0646123x1/export-citation/. Accessed 12 January 2012.
36. Dempsey JM, Mahoney SJ, Blenis J, (2010) mTORC1-Mediated Control of Protein Translation. Structure, Function and Regulation of Tor Complexes from Yeasts to Mammals Part B. Academic Press, Vol. Volume 28: 1-20.
37. Wang L, Harris TE, Roth RA, Lawrence JC, (2007) PRAS40 Regulates mTORC1 Kinase Activity by Functioning as a Direct Inhibitor of Substrate Binding. Journal of Biological Chemistry 282: 20036-20044.
38. Sabatini DM, (2006) mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 6: 729-734 doi:10.1038/nrc1974.
39. Polak P, Hall MN, (2006) mTORC2 Caught in a SINful Akt. Developmental Cell 11: 433-434 doi:10.1016/j.devcel.2006.09.005.
40. Fan Q-W, Knight ZA, Goldenberg DD, Yu W, Mostov KE, et al. (2006) A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 9: 341-349 doi:10.1016/j.ccr.2006.03.029.
41. Park S, Chapuis N, Bardet V, Tamburini J, Gallay N, et al. (2008) PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML. Leukemia 22: 1698-1706.
42. Wozniak M, Keely P, (2005) Use of three-dimensional collagen gels to study mechanotransduction in t47d breast epithelial cells. Biological Procedures Online 7: 144-161 doi:10.1251/bpo112.
43. Niforou KN, Anagnostopoulos AK, Vougas K, Kittas C, Gorgoulis VG, et al. (2008) The proteome profile of the human osteosarcoma U2OS cell line. Cancer Genomics-Proteomics 5: 63-77.
44. Ušaj M, Trontelj K, Miklavčič D, Kandušer M, (2010) Cell-Cell Electrofusion: Optimization of Electric Field Amplitude and Hypotonic Treatment for Mouse Melanoma (B16-F1) and Chinese Hamster Ovary (CHO) Cells. Journal of Membrane Biology 236: 107-116 doi:10.1007/s00232-010-9272-3.
45. Zaman MH, Trapani LM, Sieminski AL, MacKellar D, Gong H, et al. (2006) Migration of tumor cells in 3D matrices is governed by matrix stiffness along with cell-matrix adhesion and proteolysis. Proceedings of the National Academy of Sciences 103: 10889-10894.
46. Pampaloni F, Reynaud EG, Stelzer EHK, (2007) The third dimension bridges the gap between cell culture and live tissue. Nat Rev Mol Cell Biol 8: 839-845 doi:10.1038/nrm2236.
47. Harjanto D, Zaman M (2010) Matrix mechanics and receptor-ligand interactions in cell adhesion. Organic & Biomolecular Chemistry 8.
48. Chevallay B, Herbage D, (2000) Collagen-based biomaterials as 3D scaffold for cell cultures: applications for tissue engineering and gene therapy. Medical and Biological Engineering and Computing 38: 211-218 doi:10.1007/BF02344779.
49. Brekhman V, Neufeld G, (2009) A novel asymmetric 3D in-vitro assay for the study of tumor cell invasion. BMC Cancer 9: 415.
50. Serebriiskii I, Castelló-Cros R, Lamb A, Golemis EA, Cukierman E, (2008) Fibroblast-derived 3D matrix differentially regulates the growth and drug-responsiveness of human cancer cells. Matrix Biology 27: 573-585 doi:10.1016/j.matbio.2008.02.008.
51. Fujimoto D, Moriguchi T, (1978) Pyridinoline, a Non-Reducible Crosslink of Collagen. Journal of Biochemistry 83: 863-867.
52. Miller BE, Miller FR, Heppner GH, (1985) Factors Affecting Growth and Drug Sensitivity of Mouse Mammary Tumor Lines in Collagen Gel Cultures. Cancer Research 45: 4200-4205.
53. She Q-B, Solit DB, Ye Q, O'Reilly KE, Lobo J, et al. (2005) The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell 8: 287-297 doi:10.1016/j.ccr.2005.09.006.
54. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, et al. (2008) Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 118: 3065-3074 doi:10.1172/JCI34739.
55. Sos ML, Fischer S, Ullrich R, Peifer M, Heuckmann JM, et al. (2009) Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proceedings of the National Academy of Sciences 106: 18351-18356 doi:10.1073/pnas.0907325106.
56. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, et al. (2002) Herceptin-induced Inhibition of Phosphatidylinositol-3 Kinase and Akt Is Required for Antibody-mediated Effects on p27, Cyclin D1, and Antitumor Action. Cancer Research 62: 4132-4141.
57. Fallica B, Makin G, Zaman MH, (2011) Bioengineering approaches to study multidrug resistance in tumor cells. Integr Biol 3: 529-539.